Novartis Ends 2009 Primed For Diversification, Pipeline, New Leadership
Executive Summary
Novartis' abrupt announcement on Jan. 26 of leadership changes at the helm overshadowed its financial and operating news flow during its year-end 2009 earnings call
You may also be interested in...
AstraZeneca Reports Higher Profits, But Cuts R&D Jobs
AstraZeneca's patent expiry woes clear amid disappointing '09 results.
Novartis Splits Chair and CEO Positions, Names Joe Jimenez CEO
The news eclipses reports of a strong 2009, in which Novartis received 30 major regulatory approvals, and saw sales grow across major divisions
Novartis Holds Lead In Oral MS Space With Fingolimod Filing
Novartis has gained the lead in the race to market for the first oral therapy for multiple sclerosis with the NDA submission for fingolimod, a feat made possible by FDA's refusal to file the earlier NDA for Merck Serono's oral MS candidate cladribine